Literature DB >> 23516317

Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia.

Beth E Snitz1, Lisa A Weissfeld, Oscar L Lopez, Lewis H Kuller, Judith Saxton, Dilrukshika M Singhabahu, William E Klunk, Chester A Mathis, Julie C Price, Diane G Ives, Ann D Cohen, Eric McDade, Steven T Dekosky.   

Abstract

OBJECTIVE: To determine whether a high prevalence (55%) of Aβ deposition in a cohort of individuals remaining dementia-free into their 9th and 10th decades is associated with cognitive decline prior to imaging.
METHODS: A total of 194 participants (mean age 85.5 years, range 82-95) who completed the Ginkgo Evaluation of Memory Study (GEMS) and remained dementia-free subsequently completed Pittsburgh compound B-PET imaging. We examined cross-sectional associations between Aβ status and performance on a broad neuropsychological test battery completed at GEMS entry 7-9 years prior to neuroimaging. We also longitudinally examined cognition over annual evaluations using linear mixed models.
RESULTS: At GEMS screening (2000-2002), participants who were Aβ-positive in 2009 had lower performance on the Stroop test (p < 0.01) and Raven's Progressive Matrices (p = 0.05), with trend level difference for Block Design (p = 0.07). Longitudinal analyses showed significant slope differences for immediate and delayed recall of the Rey-Osterrieth figure, semantic fluency, and Trail-Making Test parts A and B, indicating greater performance decline prior to neuroimaging for Aβ-positive relative to Aβ-negative participants (ps < 0.05).
CONCLUSIONS: Highly prevalent Aβ deposition in oldest-older adults is associated with cognitive decline in visual memory, semantic fluency, and psychomotor speed beginning 7-9 years prior to neuroimaging. Mean differences in nonmemory domains, primarily executive functions, between Aβ-status groups may be detectable 7-9 years before neuroimaging.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23516317      PMCID: PMC3662268          DOI: 10.1212/WNL.0b013e31828c2fc8

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

1.  Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease.

Authors:  V L Villemagne; K E Pike; D Darby; P Maruff; G Savage; S Ng; U Ackermann; T F Cowie; J Currie; S G Chan; G Jones; H Tochon-Danguy; G O'Keefe; C L Masters; C C Rowe
Journal:  Neuropsychologia       Date:  2008-02-14       Impact factor: 3.139

2.  Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

Authors:  Joseph L Price; Daniel W McKeel; Virginia D Buckles; Catherine M Roe; Chengjie Xiong; Michael Grundman; Lawrence A Hansen; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Charles D Smith; Daron G Davis; Frederick A Schmitt; William R Markesbery; Jeffrey Kaye; Roger Kurlan; Christine Hulette; Brenda F Kurland; Roger Higdon; Walter Kukull; John C Morris
Journal:  Neurobiol Aging       Date:  2009-04-18       Impact factor: 4.673

3.  Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.

Authors:  Martha Storandt; Mark A Mintun; Denise Head; John C Morris
Journal:  Arch Neurol       Date:  2009-12

4.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.

Authors:  John C Morris; Catherine M Roe; Elizabeth A Grant; Denise Head; Martha Storandt; Alison M Goate; Anne M Fagan; David M Holtzman; Mark A Mintun
Journal:  Arch Neurol       Date:  2009-12

5.  Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B.

Authors:  Meryl A Butters; William E Klunk; Chester A Mathis; Julie C Price; Scott K Ziolko; Jessica A Hoge; Nicholas D Tsopelas; Brian J Lopresti; Charles F Reynolds; Steven T DeKosky; Carolyn C Meltzer
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703

6.  Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway.

Authors:  Ganesh M Shankar; Brenda L Bloodgood; Matthew Townsend; Dominic M Walsh; Dennis J Selkoe; Bernardo L Sabatini
Journal:  J Neurosci       Date:  2007-03-14       Impact factor: 6.167

7.  Ginkgo biloba for prevention of dementia: a randomized controlled trial.

Authors:  Steven T DeKosky; Jeff D Williamson; Annette L Fitzpatrick; Richard A Kronmal; Diane G Ives; Judith A Saxton; Oscar L Lopez; Gregory Burke; Michelle C Carlson; Linda P Fried; Lewis H Kuller; John A Robbins; Russell P Tracy; Nancy F Woolard; Leslie Dunn; Beth E Snitz; Richard L Nahin; Curt D Furberg
Journal:  JAMA       Date:  2008-11-19       Impact factor: 56.272

8.  Within-person across-neuropsychological test variability and incident dementia.

Authors:  Roee Holtzer; Joe Verghese; Cuiling Wang; Charles B Hall; Richard B Lipton
Journal:  JAMA       Date:  2008-08-20       Impact factor: 56.272

9.  Imaging beta-amyloid burden in aging and dementia.

Authors:  C C Rowe; S Ng; U Ackermann; S J Gong; K Pike; G Savage; T F Cowie; K L Dickinson; P Maruff; D Darby; C Smith; M Woodward; J Merory; H Tochon-Danguy; G O'Keefe; W E Klunk; C A Mathis; J C Price; C L Masters; V L Villemagne
Journal:  Neurology       Date:  2007-05-15       Impact factor: 9.910

10.  Frequent amyloid deposition without significant cognitive impairment among the elderly.

Authors:  Howard Jay Aizenstein; Robert D Nebes; Judith A Saxton; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Scott K Ziolko; Jeffrey A James; Beth E Snitz; Patricia R Houck; Wenzhu Bi; Ann D Cohen; Brian J Lopresti; Steven T DeKosky; Edythe M Halligan; William E Klunk
Journal:  Arch Neurol       Date:  2008-11
View more
  42 in total

1.  NLRP1 and NTN1, Deregulated Blood Differentially Methylated Regions in Mild Cognitive Impairment Patients.

Authors:  Min-Koo Park; Ji-Won Lee; Jeong-Chan Lee; Sung-Joo Hwang; Hyun Woong Roh; Chang Hyung Hong; Sang Joon Son
Journal:  J Mol Neurosci       Date:  2018-11-05       Impact factor: 3.444

2.  Arterial stiffness and β-amyloid progression in nondemented elderly adults.

Authors:  Timothy M Hughes; Lewis H Kuller; Emma J M Barinas-Mitchell; Eric M McDade; William E Klunk; Ann D Cohen; Chester A Mathis; Steven T Dekosky; Julie C Price; Oscar L Lopez
Journal:  JAMA Neurol       Date:  2014-05       Impact factor: 18.302

3.  The nuances of cognition and depression in older adults: the need for a comprehensive assessment.

Authors:  Patrick J Brown; Joel R Sneed; Bret R Rutherford; D P Devanand; Steven P Roose
Journal:  Int J Geriatr Psychiatry       Date:  2013-10-03       Impact factor: 3.485

Review 4.  Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis.

Authors:  S Duke Han; Caroline P Nguyen; Nikki H Stricker; Daniel A Nation
Journal:  Neuropsychol Rev       Date:  2017-05-11       Impact factor: 7.444

5.  Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults.

Authors:  Neelesh K Nadkarni; Oscar L Lopez; Subashan Perera; Stephanie A Studenski; Beth E Snitz; Kirk I Erickson; Chester A Mathis; Robert D Nebes; Mark Redfern; William E Klunk
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-03-01       Impact factor: 6.053

6.  Neuroimaging markers associated with maintenance of optimal memory performance in late-life.

Authors:  Maria Dekhtyar; Kathryn V Papp; Rachel Buckley; Heidi I L Jacobs; Aaron P Schultz; Keith A Johnson; Reisa A Sperling; Dorene M Rentz
Journal:  Neuropsychologia       Date:  2017-05-01       Impact factor: 3.139

7.  Sleep moderates the relationship between amyloid beta and memory recall.

Authors:  Kristine A Wilckens; Dana L Tudorascu; Beth E Snitz; Julie C Price; Howard J Aizenstein; Oscar L Lopez; Kirk I Erickson; Brian J Lopresti; Charles M Laymon; Davneet Minhas; Chester A Mathis; Daniel J Buysse; William E Klunk; Ann D Cohen
Journal:  Neurobiol Aging       Date:  2018-07-26       Impact factor: 4.673

8.  Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.

Authors:  Yujing Zhao; Dana L Tudorascu; Oscar L Lopez; Ann D Cohen; Chester A Mathis; Howard J Aizenstein; Julie C Price; Lewis H Kuller; M Ilyas Kamboh; Steven T DeKosky; William E Klunk; Beth E Snitz
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

9.  Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease.

Authors:  Ian M McDonough; Gérard N Bischof; Kristen M Kennedy; Karen M Rodrigue; Michelle E Farrell; Denise C Park
Journal:  Neurobiol Aging       Date:  2016-06-25       Impact factor: 4.673

10.  Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease.

Authors:  Kathryn V Papp; Elizabeth C Mormino; Rebecca E Amariglio; Catherine Munro; Alex Dagley; Aaron P Schultz; Keith A Johnson; Reisa A Sperling; Dorene M Rentz
Journal:  Neuropsychology       Date:  2015-11-23       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.